Where are the products exported to?

The products have been sold to countries and regions in South America, Africa, Asia, Southeast Asia, Oceania, and the Middle East.

What is the lead time for peak season?

The peak season lead time is one month.

What payment terms are accepted?

Accepted payment terms include LC and T/T.

0.9% Sodium Chloride Injection 4000ml Plastic Bag

Name: 0.9% Sodium Chloride Injection 4000ml Plastic Bag
Brand: Shijiazhuang No. 4 Pharmaceutical Co., Ltd.
SKU: 2200402105

Hebei, ChinaShijiazhuang No. 4 Pharmaceutical Co., Ltd.

US$0.23-0.25

10,000 Pieces

Sample price:US$0.20/piece.Request sample

Product profile

Customization

Available

Application

Internal Medicine

Usage Mode

Infusion

Suitable for

Elderly, Children, Adult

State

Liquid

Shape

Infusion

Type

Inorganic Chemicals

Pharmaceutical Technology

Chemical Synthesis

Transport Package

Carton

Specification

500ml

Trademark

SHIMEN

Origin

China

HS Code

3004909099

Production Capacity

1000000

Key features

Broad Application Range: Suitable for elderly, children, and adults for internal medicine infusion.

Versus Dehydration Treatment: Indicated for dehydration caused by hypoosmolality, isotonia, and hypertonicity.

Metabolic Alkali Poisoning: Effective treatment for low-chloride metabolic alkali poisoning.

External Use Capability: Can be used externally to wash eyes and wounds.

Labor Induction Support: Can be used for the induction of labor with water bag.

GMP Certified Manufacturer: Produced by Shijiazhuang No.4 Pharmaceutical Co., Ltd. with SFDA GMP approval.

High Production Capacity: Yearly output exceeds 1200 million bottles for large volume I.V solutions.

Global Market Reach: Products sold to South America, Africa, Asia, and other international regions.

Company profile

Shijiazhuang No. 4 Pharmaceutical Co., Ltd.

Hebei, China

Business Type: Manufacturer/FactoryExport Year: 2002-01-01Nearest Port: Tianjin Xingang, Qingdao, ShanghaiAverage Response Time: ≤24hTerms of Payment: LC, T/TInternational Commercial Terms(Incoterms): FOB, CFR, CIF, CIP, EXW

AI-Powered supplier vetting

SummaryShijiazhuang No. 4 Pharmaceutical Co., Ltd. is identified as a Chinese public pharmaceutical manufacturer based in Hebei, with products spanning infusion solutions, injections, tablets, capsules, inhalation products, and other medical materials. The supplier reports ISO 9001, ISO 14001, and GMP certifications, more than ten production lines, automated and information-based production and logistics processes, and substantial stated output across several dosage forms. Its export activity began in 2002, although exports represent only 1%–10% of total sales. The company describes integrated R&D, manufacturing, and marketing capabilities, but the provided information does not establish specific after-sales programs, customization services, or named customer cases. Financial strength cannot be assessed because financial data is excluded.

Supplier typeThe supplier is explicitly classified as a Manufacturer/Factory and is described as an integrated pharmaceutical enterprise covering R&D, industrial production, and marketing. Its listed business covers health and medicine products, including injections, infusion solutions, tablets, capsules, and related dosage forms.

CertificationsThe supplier reports ISO 9001, ISO 14001, and GMP certifications. It also states that production is organized strictly according to GMP requirements, providing explicit evidence of formal quality, environmental, and pharmaceutical manufacturing systems.

R&D capabilityThe supplier describes an integrated R&D, production, and marketing model, reports 50 R&D engineers, and states that its production lines integrate leading equipment and technology at an international advanced level. This supports established technical and development capability, although no specific patents, new-product results, or R&D investment details are provided.

Production capacityProduction capability is strongly supported by more than ten production lines, automated and information-based production and logistics processes, and stated annual outputs of 1.5 billion large-volume injection units and 1 billion units each for tablets, capsules, and small-volume injections. The company also reports more than ten international advanced infusion-solution lines and exports through both agency and self-operated channels.

Product Q&A

Q:What is the main indication for this product?

It is indicated for dehydration caused by various cases including hypoosmolality, isotonia, and hypertonicity, as well as low-chloride metabolic alkali poisoning.

Q:Who can use this injection?

It is suitable for elderly, children, and adults.

Q:Can this product be used for external purposes?

Yes, external use sodium chloride can be used to wash the eyes and wounds.

Q:What is the manufacturer's background?

Shijiazhuang No.4 Pharmaceutical Co., Ltd. was established in 1948, is a large-sized foreign invested enterprise with over 3000 employees and GMP approval.

Q:What is the production capacity of the manufacturer?

The yearly output for large volume I.V solutions has reached more than 1200 million bottles.